Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115704) titled 'Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined with Palliative Transarterial Chemoembolization Followed by Targeted Immunotherapy in Unresectable BCLC Stage C Hepatocellular Carcinoma' on Dec. 30, 2025.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Affiliated Hospital of Yanbian University
Condition:
BCLC Stage C Hepatocellular Carcinoma
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2025-12-30
Target Sample Size: Experimental Group:30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj...